Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorComputer and Technology
CIKN/A
Phone888-280-2221
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.78 billion
Profitability
Miscellaneous
Employees5,000
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Covetrus (NASDAQ:CVET) Frequently Asked Questions
What is Covetrus' stock symbol?
Covetrus trades on the NASDAQ under the ticker symbol "CVET."
How were Covetrus' earnings last quarter?
Covetrus Inc (NASDAQ:CVET) posted its quarterly earnings results on Tuesday, August, 13th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.16 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.05 billion. View Covetrus' Earnings History.
When is Covetrus' next earnings date?
What price target have analysts set for CVET?
8 brokerages have issued 12-month price targets for Covetrus' stock. Their predictions range from $11.00 to $21.00. On average, they expect Covetrus' stock price to reach $15.25 in the next year. This suggests a possible upside of 43.2% from the stock's current price. View Analyst Price Targets for Covetrus.
What is the consensus analysts' recommendation for Covetrus?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Covetrus.
Has Covetrus been receiving favorable news coverage?
Media stories about CVET stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Covetrus earned a daily sentiment score of -2.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Covetrus.
Who are some of Covetrus' key competitors?
What other stocks do shareholders of Covetrus own?
Who are Covetrus' key executives?
Covetrus' management team includes the folowing people:
- Benjamin J. Shaw, President, Chief Executive Officer & Director
- Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
- Matthew Leonard, Executive VP & President-North America
- Jim Young, Chief Human Resources Officer & Senior VP
- Erin Powers Brennan, Secretary, Senior Vice President & General Counsel
Who are Covetrus' major shareholders?
Covetrus' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.03%), Bridge Creek Capital Management LLC (0.02%), State of Alaska Department of Revenue (0.02%), Nisa Investment Advisors LLC (0.01%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%) and M&R Capital Management Inc. (0.00%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Erin Powers Brennan and Timothy Ludlow. View Institutional Ownership Trends for Covetrus.
Which major investors are buying Covetrus stock?
CVET stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Bridge Creek Capital Management LLC, State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Nelson Van Denburg & Campbell Wealth Management Group LLC and M&R Capital Management Inc.. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw and Erin Powers Brennan. View Insider Buying and Selling for Covetrus.
How do I buy shares of Covetrus?
Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Covetrus' stock price today?
One share of CVET stock can currently be purchased for approximately $10.65.
How big of a company is Covetrus?
What is Covetrus' official website?
How can I contact Covetrus?
Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]
MarketBeat Community Rating for Covetrus (NASDAQ CVET)
MarketBeat's community ratings are surveys of what our community members think about Covetrus and other stocks. Vote "Outperform" if you believe CVET will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVET will underperform the S&P 500 over the long term. You may vote once every thirty days.
